Emcitate (tiratricol)

Name: Emcitate (tiratricol) in MCT8 deficiency: Indication
Published: 2026-09-14T15:39:06-04:00

MCT8 deficiency

Manufacturer: Egetis Therapeutics
Regulatory submission: NDA submitted January 2026 and approved September 2026
Launch: Anticipated eight to ten weeks after the September 2026 approval
Last updated: September 29, 2026

Section

Product information and disease description Product description Product information

Indication

2 evidence topics · 2 sources

U.S. indication and limitation of use

“EMCITATE is indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley syndrome).” (opens the prescribing information at this quote)
“EMCITATE is not recommended for the treatment of primary hypothyroidism.” (opens the prescribing information at this quote)

European Union therapeutic indication

“Emcitate is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.” (opens the source at this quote in a new tab)